-
B180012-100mg7-Bromoisoquinolin-3-amine.
-
B179514-250mg5-Bromo-8-fluoroquinoline.
-
B179514-1g5-Bromo-8-fluoroquinoline.
-
B178252-250mgProduct Describtion:RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes drug resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity. RRx-001 is
-
B177582-100mg4-Bromo-3-nitropyridin-2-amine.
-
B177489-5mgAvanbulin (BAL27862) is a potent, Colchicine site-binding, tubulin assembly inhibitor. Avanbulin inhibits tubulin assembly at 37 °C with an IC50 of 1.
-
B177489-50mgAvanbulin (BAL27862) is a potent, Colchicine site-binding, tubulin assembly inhibitor. Avanbulin inhibits tubulin assembly at 37 °C with an IC50 of 1.
-
B177489-25mgAvanbulin (BAL27862) is a potent, Colchicine site-binding, tubulin assembly inhibitor. Avanbulin inhibits tubulin assembly at 37 °C with an IC50 of 1.
-
B177489-10mgAvanbulin (BAL27862) is a potent, Colchicine site-binding, tubulin assembly inhibitor. Avanbulin inhibits tubulin assembly at 37 °C with an IC50 of 1.
-
B176935-100mg4-Bromo-2-methyl-1H-indole.
-
B176828-25g7-bromo-4-chloroquinazoline.
-
B169477-200mg7-Bromothieno[3,2-d]pyrimidin-4(1H)-one.